The Biomarkers Consortium’s Cancer, Inflammation and Immunity, Metabolic Disorders and Neuroscience Steering Committees are responsible for identifying and moving forward promising pre-competitive biomarkers projects for implementation by the Biomarkers Consortium, as well as overseeing each individual project under its purview. The members of each Steering Committee represent a variety of sectors, including academia, government, industry and not-for-profit/advocacy organizations, and are led by two co-chairs representing two of the following three sectors: academia, government or industry.
| Thierry Sornasse, Ph.D., AbbVie (Co-Chair)
David Fox, M.D., University of Michigan (Co-Chair) Alexandre Akoulitchev, M.A., Ph.D., Oxford Biodynamics Anne-Christine Bay-Jensen, Ph.D., Nordic Biosciences A/S Kristina Beeler, Ph.D., Ms.C., Biognosys Robert Benschop, Ph.D., Eli Lilly Anna Berdine, M.S., Alamar Biosciences Maria Bettinotti, Ph.D., Johns Hopkins University Jonathon Brzezinski, Ph.D., Clarivate Preethi Chander, Ph.D., NIDCR/NIH Laurence Cheng, M.D., Ph.D., Amgen Kelly Chun, Ph.D., LabCorp Janet Church, Sjögren’s Foundation Albert Crescenzo, Ph.D., Clarivate Carolyn Cuff, Ph.D., Janssen Thomas Daly, M.D., Eli Lilly Sahar Dawisha, M.D., FDA/CDRH Natasha de Peyrecave, D. Phil., UCB Betty Diamond, Ph.D., Feinstein Institute Renee Donahue, Ph.D., NIH/NCI Ed Driggers, Ph.D., General Metabolics Kellie Feck, Olink Carol Feghali-Bostwick, Ph.D., National Scleroderma Foundation Julie Fiore, M.D., Ph.D., Merck Dan Fitzpatrick, Ph.D., Amgen Thomas Fuerst, Ph.D., Clario Rebecca Fuldner, Ph.D., NIH/NIA Alessandra Geremia, Ph.D., GSK Mireia Guerau, PharmD, Ph.D., NIH/NIAID Kathy Hammitt, M.A., Sjogren’s Foundation Stephanie Hennek, Ph.D., PathAI Andrea Hooper, Ph.D, Regeneron Ewan Hunter, Oxford Biodynamics Andres Hurtado-Lorenzo, Crohn’s & Colitis Foundation Angelika Jahreis, Novartis Christina Jayson, Path AI Chao Jiang, Ph.D., NIAID/NIH Daniel Johnston, Ph.D., NIH/NICHD Kathy Jung, Ph.D., NIH/NIAAA Jason Kim, Ph.D., Arthritis Foundation Ernst Kriehuber, M.D., UCB Stephen Laroux, Ph.D., AbbVie Steven Leonard, Johnson & Johnson |
David Martin, M.D., Pfizer
Russell McBride, Ph.D., MPH, Icahn School of Medicine at Mount Sinai Andrea Mortera, Empatica Alan Moss, M.D,. Crohn’s & Colitis Foundation of America Sumanta Mukherjee, Ph.D., GlaxoSmithKline Raj Nair, Ph.D., FDA/CDER Nikolay Nikolov, M.D., FDA/CDER Mariaelena Occhipinti, M.D., Ph.D., Radiomics Heiyoung Park, Ph.D., NIAMS/NIH Jane Parnes, M.D., Amgen Brian Porter, M.D., Ph.D., M.P.H., M.B.A., Novartis Josh Porter, Olink Proteomics Rubio Punzalan, Ph.D., LabCorp John Reveille, M.D., University of Texas Health Science Center (Houston) Lisa Rider, M.D., NIH/NIEHS Mert Sahin, Ph.D., Durin Technologies Jane Salmon, M.D., Hospital for Special Surgery Johannes Scheid, M.D., Ph.D., Merck Adam Schiffenbauer, M.D., NIH/NIEHS Maggie Scully, Ph.D., Frederick National Laboratory for Cancer Research Susana A. Serrate-Sztein, M.D., NIH/NIAMS Vicki Shanmugam, MBBS, MRCP, FACR, CCD, NIH / OADR Diane Shevell, Ph.D., Novartis Glennda Smithson, Ph.D., Takeda Lisa Spain, Ph.D., NIH/NIDDK Emily Boyd Stormoen, Arthritis National Research Foundation Mark Tengowski, Ph.D., Clario Paresh Thakker, Ph.D., Takeda Mulualem Tilahun, DVM, Ph.D., NIH/NIA/DAB Candance Tingen, Ph.D., NIH/NICHD Marco Tognetti, Biognosys Sudha Visvanathan, Ph.D., Boehringer Ingelheim Wim Vos, Ph.D., Radiomics Tony Wagner, Ph.D., Jazz Pharmaceuticals Joe Wang, Ph.D., NIH/NIAAA Ilan Wapinski, Ph.D., Sanofi Michael Weisman, M.D., Stanford University Mary Wheatley, CAE, National Scleroderma Foundation Michael Whitfield, Ph.D., Dartmouth Geisel School of Medicine Joel Wommack, Ph.D., SomaLogic Jennifer Yoon, Somalogic Jad Zoghbi, M.S., Biogen |